CTI submits expanded PIP to EMEA for pixantrone MAA for refractory or relapsed.

announced today that it offers submitted an expanded Pediatric Investigation Plan to the European Medications Agency , as part of the process for its submission for a Marketing Authorization Software for pixantrone in the E.U. For the treatment of refractory or relapsed, aggressive non-Hodgkin’s lymphoma . In September 2009 KlegermanCTI submitted the initial PIP. ‘Our discussions with the pediatric professionals on the PDCO indicated that they agree with our belief that the need for a much less toxic, more effective anthracycline-like agent is usually significant, not merely in lymphoma, but possibly in other tumors. ‘Filing the updated PIP puts us one step closer to completing the MAA submission process, and moves us towards our objective of making pixantrone open to suitable patients.’..We likewise have a regulatory body to make sure that appropriate boundaries could be arranged. Related StoriesMD Anderson research reveals why chemotherapy medicines not effective for most pancreatic cancers patientsViralytics enters into scientific trial collaboration contract with MSDSausages With Antioxidants From Berries TO AVOID Cancer.

Botswana launches baby HIV testing program Botswana in a ceremony in Francistown – – attended by Mark Dybul, who acts seeing that the U.S. Global Helps coordinator and administers the President’s Emergency Arrange for AIDS Alleviation – – launched an application to test six-month-outdated infants for HIV, regarding a U.S. Embassy declaration released on Wednesday, SAPA/SABC News reviews.